Cargando…
The TOUCH program and natalizumab: Fundamental flaw in patient protection
Many drugs have been approved by the Food and Drug Administration (FDA) since 1993 for treatment of relapsing forms of multiple sclerosis (MS). One such drug is natalizumab (Tysabri, Biogen Idec and Elan pharmaceuticals) which has enjoyed great success in the management of MS since its re-introducti...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
F1000Research
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837976/ https://www.ncbi.nlm.nih.gov/pubmed/27134725 http://dx.doi.org/10.12688/f1000research.7513.3 |